Subtherapeutic triazole concentrations as result of a drug-drug interaction with lumacaftor/ivacaftor

Research output: Contribution to journalArticleAcademicpeer-review

5 Downloads (Pure)


Lumacaftor/ivacaftor (Orkambi®, LUM/IVA) is indicated for the treatment of cystic fibrosis (CF) patients aged ≥ 2 years with homozygous F580del mutation in the CFTR gene. Triazole fungal agents are used to treat fungal disease in CF. The use of triazoles is limited by pharmacokinetic challenges, such as drug-drug interactions. The most notable drug-drug interaction between triazoles and LUM/IVA is due to strong induction of CYP3A4 and UGT by LUM. In this real-world retrospective observational study, we described the effect of LUM/IVA on the trough concentration of triazoles. Concomitant use of LUM/IVA with itraconazole, posaconazole or voriconazole resulted in subtherapeutic triazole levels in 76% of the plasma samples. In comparison, in patients with triazole agents without LUM/IVA only 30.6% of the plasma samples resulted in subtherapeutic concentrations. Subtherapeutic plasma concentrations of triazoles should be considered in CF patients on LUM/IVA and further research is warranted for other dosing strategies and alternative antifungal therapy.

Original languageEnglish
JournalJournal of Cystic Fibrosis
Publication statusE-pub ahead of print - 27 Jan 2024

Bibliographical note

Publisher Copyright:
© 2024 The Author(s)


Dive into the research topics of 'Subtherapeutic triazole concentrations as result of a drug-drug interaction with lumacaftor/ivacaftor'. Together they form a unique fingerprint.

Cite this